80 completed. 80 Phase 2, 13 Phase 3, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 80 | Completed 80 |
| Phase 3 | 13 | Completed 13 |
| Phase 1 | 9 | Completed 9 |
Follow Fibromyalgia: new trials by email Literature Review of Fibromyalgia trials Research Report on Fibromyalgia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia Lidocaine and Dexamethasone, Normal Saline - Fibromyalgia | Phase 2 / Phase 3 | Completed | Sanliurfa Education and Research Hospital | 68 | 2025-06-01 | 2026-01-16 |
| A Clinical Study of ONO-1110 in Patients With Fibromyalgia ONO-1110, Placebo - Fibromyalgia | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 175 | 2025-03-26 | 2026-07-07 |
| Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia Psilocybin, Psychotherapy - Fibromyalgia | Phase 2 | Completed | Kevin Boehnke | 17 | 2023-09-27 | 2025-04-16 |
| A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome rozanolixizumab, Placebo - Fibromyalgia | Phase 2 | Completed | UCB Biopharma SRL | 63 | 2022-12-21 | 2025-07-01 |
| Reconsolidation Therapy With Propranolol as a Treatment for Chronic Pain Propranolol Hydrochloride, Placebo, Reactivation procedure - Chronic Low-back Pain, Fibromyalgia | Phase 2 | Completed | Université de Sherbrooke | 48 | 2022-02-07 | 2025-09-26 |
| The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo, Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily) - Fibromyalgia | Phase 1 / Phase 2 | Completed | Medical University of South Carolina | 14 | 2021-12-06 | 2024-01-30 |
| Impact of Post-Traumatic Stress Disorder Treatment by Reconsolidation Therapy on Fibromyalgia Syndrome Propranolol - Fibromyalgia Syndrome, Posttraumatic Stress Disorder | Phase 2 | Completed | Centre Hospitalier Henri Laborit | 17 | 2021-08-13 | 2026-09-09 |
| Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1 IMC-1, Placebo BID Tablet - Fibromyalgia | Phase 2 | Completed | Virios Therapeutics, Inc. | 422 | 2021-06-03 | 2022-09-27 |
| Treating Negative Affect in Low Back Pain Patients Antidepressant, Enhanced Fear Avoidance Rehabilitation - Chronic Low Back Pain, Negative Affectivity | Phase 2 | Completed | Ajay Wasan, MD, Msc | 308 | 2021-03-31 | 2026-08-28 |
| Fibromyalgia and Naltrexone: The FINAL Study Naltrexone Pill, Placebo oral tablet - Fibromyalgia | Phase 2 | Completed | Odense University Hospital | 99 | 2021-01-06 | 2022-12-29 |
| "SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia Digital ACT, Digital Symptom Tracker - Fibromyalgia | Phase 2 | Completed | Swing Therapeutics, Inc. | 67 | 2020-10-28 | 2023-08-01 |
| The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia Endotoxin, Escherichia Coli, Magnetic Resonance Spectroscopy - Fibromyalgia | Phase 2 / Phase 3 | Completed | University of Alabama at Birmingham | 36 | 2020-03-11 | 2023-04-14 |
| The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Pyridostigmine Bromide, Placebo - Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome | Phase 2 | Completed | Brigham and Women's Hospital | 45 | 2020-01-14 | 2022-11-08 |
| Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia NYX-2925, Placebo - Fibromyalgia | Phase 2 | Completed | Aptinyx | 310 | 2019-11-12 | 2023-04-28 |
| Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments 5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream - Vestibulodynia, Temporomandibular Disorder | Phase 2 | Completed | Duke University | 209 | 2019-11-04 | 2026-03-19 |
| Evaluation of the Efficiacy of Mecobalamine in the Treatment of Long-term Pain in Women Diagnosed With Fibromyalgia Mecobalamin 5 MG, Placebo Comparator : NaCl 9 mg/ml - Fibromyalgia | Phase 1 / Phase 2 | Completed | Linnaeus University | 40 | 2019-02-06 | 2024-12-18 |
| LDN and tDCS in Fibromyalgia Low-Dose Naltrexone, Transcranial Direct Current Stimulation, Placebo - Fibromyalgia | Phase 2 / Phase 3 | Completed | Centro Universitario La Salle | 92 | 2018-08-01 | 2020-08-06 |
| Dextromethorphan in Fibromyalgia Dextromethorphan, Placebo - Fibromyalgia | Phase 2 | Completed | University of Alabama at Birmingham | 27 | 2018-06-26 | 2022-08-26 |
| Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia Duloxetine, Escitalopram - Fibromyalgia | Phase 2 / Phase 3 | Completed | Shaheed Zulfiqar Ali Bhutto Medical University | 200 | 2018-04-09 | 2020-02-27 |
| Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia NYX-2925, Placebo oral capsule - Fibromyalgia | Phase 2 | Completed | Aptinyx | 22 | 2017-08-14 | 2022-09-16 |
Showing 20 of 80. Sign in to see all of them.
Chronic Pain (13) · Pain (12) · Motor Activity (5) · Fatigue (4) · Fatigue Syndrome, Chronic (4) · Back Pain (2) · Depression (2) · Irritable Bowel Syndrome (2) · Migraine Disorders (2) · Agnosia (1) · Anxiety Disorders (1) · Arthritis (1) · Autonomic Nervous System Diseases (1) · Cystitis, Interstitial (1)
Nervous System Diseases (80) · Neuromuscular Diseases (80) · Rheumatic Diseases (80) · Muscular Diseases (79) · Musculoskeletal Diseases (79) · Pathological Conditions, Signs and Symptoms (30) · Signs and Symptoms (29) · Neurologic Manifestations (27) · Pain (14) · Behavior (9) · Pathologic Processes (5) · Central Nervous System Diseases (4) · Chronic Disease (4) · Disease Attributes (4) · Encephalomyelitis (4)
Exercise (5) · Duloxetine Hydrochloride (3) · Transcranial Direct Current Stimulation (3) · Amitriptyline (2) · Control Groups (2) · Escitalopram (2) · Milnacipran (2) · Mirtazapine (2) · NYX-2925 (2) · Naltrexone (2) · Physical Therapy Modalities (2) · Propranolol (2) · Pyridostigmine Bromide (2) · Saline Solution (2) · Venlafaxine Hydrochloride (2)
National Center for Complementary and Integrative Health (NCCIH) (4) · University of Michigan (3) · University of Washington (3) · Aptinyx (2) · Astellas Pharma Global Development, Inc. (2) · Duke University (2) · UCB Pharma (2) · University of Alabama at Birmingham (2) · Ajay Wasan, MD, Msc (1) · American Regent, Inc. (1) · Avacen, Inc. (1) · Bennett, Robert, M.D. (1) · Beth Israel Medical Center (1) · Bial - Portela C S.A. (1) · Brigham and Women's Hospital (1)
United States (49) · Canada (5) · United Kingdom (4) · Spain (3) · Belgium (2) · Brazil (2) · Denmark (2) · France (2) · Germany (2) · Sweden (2) · Australia (1) · Finland (1) · Italy (1) · Japan (1) · Netherlands (1)
Dennis C. Turk, PhD (2) · Ajay Wasan, MD, MSc (1) · Akiko Okifuji, PhD (1) · Albert Nadal, MD (1) · Alexandre DaSilva, DDS, MS (1) · Andrea Nackley, PhD (1) · Benjamin H Natelson, MD (1) · Brian Feldman, MSc MD FRCPC (1) · Carina Elmqvist, Ass prof (1) · Christopher France, PhD (1) · Daniel J. Clauw, MD (1) · David A. Williams, PhD (1)
PMID 11764222, PMID 15556826, PMID 15943960, PMID 17133529, PMID 18053120, PMID 18311814, PMID 18821656, PMID 19250003, PMID 19369473, PMID 20828282, PMID 21772818, PMID 22336292, PMID 23618477, PMID 24251273, PMID 24868587, PMID 25371383, PMID 25660434, PMID 26335989, PMID 29149437, PMID 29870396, PMID 30419855, PMID 30510505, PMID 32131045, PMID 32856281, PMID 33328761, PMID 34781989, PMID 35526605, PMID 36269028, PMID 36715655, PMID 36997252, PMID 37382794, PMID 38258677, PMID 40171515, PMID 41595724, PMID 42431386, PMID 42530408, PMID 42748952, PMID 42830128, PMID 42857927
R01AR044724 (2), 2019 (1), K01AT001111 (1), P50AT000084 (1), R01AR044020 (1), R01AR044064 (1), R01AR048888 (1), R01AR050044 (1), R01AR052368 (1), R01HD096331 (1), R01NR008150 (1), R21AR053963 (1), UG3AR076568 (1)